Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21009793 | 0.95 | MEN1 (0.46) | P2RX7MEN1KMT2ACTSLCTSB | |
| SCHEMBL24940832 | 0.94 | CTSL (0.45) | P2RX7MEN1KMT2AALOX15TSHR | |
| SCHEMBL2797417 | 0.92 | MEN1 (0.46) | P2RX7MEN1KMT2ACTSLCTSB | |
| SCHEMBL25597457 | 0.90 | BACE1 (0.43) | P2RX7MEN1KMT2ATSHRCTSL | |
| SCHEMBL3205700 | 0.90 | CTSS (0.47) | P2RX7MEN1KMT2ACTSLCTSB | |
| SCHEMBL2206561 | 0.89 | MEN1 (0.47) | P2RX7MEN1KMT2ACTSLCTSB | |
| SCHEMBL2208865 | 0.88 | OPRD1 (0.47) | P2RX7MEN1KMT2ACTSLCTSB | |
| SCHEMBL2798332 | 0.87 | CTSL (0.49) | P2RX7MEN1KMT2AALOX15TSHR | |
| SCHEMBL6507749 | 0.86 | MEN1 (0.44) | P2RX7MEN1KMT2AALOX15TSHR | |
| SCHEMBL17766785 | 0.86 | OPRD1 (0.46) | P2RX7MEN1KMT2ACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| EP-2231687-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | Sun Pharma Advanced Research Company Limited (IN) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009116067-A2 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | NR1D2, STARD10, NR1D1 | P2RX7 2120/4885MEN1 4323/4885KMT2A 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.